Mydecine Innovations Group Inc (OTCMKTS:MYCO) looks forward to starting its Phase 2A PTSD clinical trials and sees ethica CRO (“ethica CRO”) as an ideal partner. After considering its excellent work towards introducing a new ethical dimension to clinical research, the business giant has chosen the partner.
The other thing that makes the partner ideal is that it became the first CRO to receive accreditation as a significant player in a human research protection program conducted back in 2006. Some people would also see the CRO getting accreditation from about three accrediting bodies as a significant achievement and qualification for the new partnership.
The CEO of Mydecine Innovations Group, Josh Bartch, applauded the move to collaborate with such a top-class partner. He hopes that the CRO’s outstanding expertise in managing clinical studies will be a great addition to their success in the upcoming Phase 2A PTSD clinical trials.
The official sees the move to bring onboard the new partner to show their outstanding preparations towards discovering how the brain reacts to psychedelics. The parties will also be looking to establish what a psychedelic experience could cause in biological underpinnings.
Mydecine wants to push its clinical development to the pinnacle, and it will be counting on its partner’s unparalleled experience in wide-ranging trials. Ethica CRO is known for its deep clinical expertise and will help a lot with the trial preparations.
The Managing Director of ethica CRO Murray Jensen is happy about the impressive mental health treatment changes. He terms Psychedelics and psychedelic-assisted therapies as some of the game-changers as they continue to progress with their innovation drive.
Mydecine is pleased to announce its partnership with Microdose Psychedelic Insights, a move that will see the two focus on unveiling a free, live webinar series. Reports show that the series will entirely focus on the Renaissance of Psychedelics.
NewAge Inc. (NASDAQ:NBEV) Expanding Its Operations In Europe As Lucim™ Gets Recognition As A Safe Skincare Product
Post Views: 359 NewAge Inc. (NASDAQ:NBEV) announced a record net revenue increase in Europe, record attendance at its virtual events,...
ILUS International Inc. (OTCMKTS:ILUS) Appoints New Marketing Director Dejana Radonjic To Help With Global Marketing
Post Views: 320 ILUS International Inc. (OTCMKTS:ILUS) seems more focused on making new acquisitions, with about two accomplished within its...
Conservative Broadcast Media Journalism (OTCMKTS:CBMJ) Reports Revenues Of $2.4 Million In 2020
Post Views: 389 Conservative Broadcast Media Journalism (OTCMKTS:CBMJ) posted a robust growth of 118% YoY to $2.4 million in 2020. Development...
Cannabics Pharmaceuticals (OTCMKTS:CNBX) Initiates RCC-33 Dose-Response Study, And Cresco Labs (OTCMKTS:CRLBF) Launches Wonder Wellness Gummies
Post Views: 358 Cannabics Pharmaceuticals (OTCMKTS:CNBX) has announced that it will initiate a Dose-Response in-vivo Study in mice whose data...
Curaleaf Holdings Inc. (OTCMKTS:CURLF) Rebrands And Opens New Locations In Pennsylvania And Illinois
Post Views: 397 Curaleaf Holdings Inc. (OTCMKTS:CURLF) has announced new Curaleaf branding for its recently acquired retail locations and the...
Generex Biotechnology Corp’s (OTCMKTS:GNBT) NuGenerex Immuno-Oncology Responds To FDA Regarding Its Paediatric-Focused COVID-19 Vaccine
Post Views: 368 Generex Biotechnology Corp’s (OTCMKTS:GNBT) subsidiary NuGenerex Immuno-Oncology has announced the submission of a response to the FDA’s...